Cargando…

Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer

ABSTRACT: BACKGROUND: Surgical resection of metastatic disease in patients with initially non-resectable colorectal cancer (CRC) has improved overall survival. Intensified chemotherapy regimens have increased the probability of converting unresectable metastasis to resectable. Here, we report the re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elshenawy, Mahmoud A., Badran, Ahmed, Aljubran, Ali, Alzahrani, Ahmed, Rauf, M. Shahzad, Eldali, Abdelmoneim, Bazarbashi, Shouki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346377/ https://www.ncbi.nlm.nih.gov/pubmed/32641137 http://dx.doi.org/10.1186/s12957-020-01930-8

Ejemplares similares

Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
por: Badran, Ahmed, et al.
Publicado: (2020)

The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-Line Chemotherapy
por: Bazarbashi, Shouki, et al.
Publicado: (2019)

Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
por: Bazarbashi, Shouki, et al.
Publicado: (2023)

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study
por: Aljubran, Ali, et al.
Publicado: (2019)

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
por: Bazarbashi, Shouki, et al.
Publicado: (2015)

Prognostic significance of peritoneal metastasis from colorectal cancer treated with first-line triplet chemotherapy
por: Bazarbashi, Shouki, et al.
Publicado: (2022)

Characteristics and outcomes of small bowel adenocarcinoma: 14 years of experience at a single tertiary hospital in Saudi Arabia
por: Alshamsan, Bader, et al.
Publicado: (2023)

Outcomes and Prognostic Factors of Metastatic Gastric Cancer: A Single-Center Experience
por: Aseafan, Mohamed, et al.
Publicado: (2022)

Neoadjuvant concurrent chemoradiotherapy using infusional gemcitabine in locally advanced rectal cancer: A phase II trial
por: Bazarbashi, Shouki, et al.
Publicado: (2022)

Elicitation of Health Utilities in Oncology in the Kingdom of Saudi Arabia
por: Iskedjian, Michael, et al.
Publicado: (2020)

Thromboembolic Events Burden in Patients With Solid Tumors and Their Predisposing Factors
por: Bazarbashi, Shouki, et al.
Publicado: (2022)

Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer
por: van Nassau, Sietske C., et al.
Publicado: (2021)

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
por: Bazarbashi, Shouki N., et al.
Publicado: (2016)

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
por: Xu, Wei, et al.
Publicado: (2016)

Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre
por: Bazarbashi, Shouki, et al.
Publicado: (2023)

Individualized prediction of survival benefit from primary tumor resection for patients with unresectable metastatic colorectal cancer
por: Yang, Yi, et al.
Publicado: (2020)

Why local guidelines?
por: Bazarbashi, Shouki
Publicado: (2011)

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
por: Antoniotti, Carlotta, et al.
Publicado: (2022)

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
por: Loupakis, Fotios, et al.
Publicado: (2015)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
por: Bruera, Gemma, et al.
Publicado: (2013)

The outcome of primary tumor resection in the unresectable stage IV colorectal cancer patients who received the bevacizumab-containing chemotherapy
por: Yeom, Seung-Seop, et al.
Publicado: (2020)

Saudi Oncology Society clinical management guidelines development
por: Bazarbashi, Shouki N.
Publicado: (2014)

Surgical and oncological outcome after laparoscopic versus open nephroureterectomy for non-metastatic, upper-tract urothelial carcinoma: A single-centre experience
por: Alothman, Khalid I., et al.
Publicado: (2020)

The Relationship between 25 (OH) D Levels (Vitamin D) and Bone Mineral Density (BMD) in a Saudi Population in a Community-Based Setting
por: Alkhenizan, Abdullah, et al.
Publicado: (2017)

Triplet‐drug chemotherapy combined with anti‐EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis
por: Tian, Muyou, et al.
Publicado: (2023)

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
por: Zhang, Xin, et al.
Publicado: (2021)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
por: Yang, Hannah, et al.
Publicado: (2023)

Saudi Oncology Society clinical management guideline series: Pancreatic cancer 2014
por: Rahal, Mohammed M., et al.
Publicado: (2014)

Utilization and cost of electronic resources in adult cancer center
por: Maraiki, Fatma, et al.
Publicado: (2018)

Emergency department attendance patterns during Ramadan
por: Butt, Taimur, et al.
Publicado: (2016)

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer
por: Mehrzad, Valiollah, et al.
Publicado: (2016)

Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
por: Bruera, Gemma, et al.
Publicado: (2012)

Saudi Oncology Society clinical management guideline series: Gastric cancer 2014
por: Kandil, Magdy S., et al.
Publicado: (2014)

Saudi Oncology Society clinical management guideline series: Esophageal cancer 2014
por: Alzahrani, Ali M., et al.
Publicado: (2014)

Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy
por: Peng, Yu, et al.
Publicado: (2018)

Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?
por: Rosumeck, Nathalie, et al.
Publicado: (2021)

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma 2017
por: Alsharm, Abdullah, et al.
Publicado: (2018)

Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017
por: Alharbi, Hulayel, et al.
Publicado: (2018)

Saudi Oncology Society clinical management guideline series: Anal canal cancer 2014
por: Bazarbashi, Shouki N., et al.
Publicado: (2014)

Chemotherapy and Targeted Therapy Strategies in Patients with Unresectable or Borderline Resectable Metastatic Colorectal Cancer: Evidence for a Lack of Focus on Resection Rates
por: Zmuc, Jan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oidfiiuobjkj8cvcmcb943u99m